Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Anastrozole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 known ✓ | P11511 | 18/20 | 0.90 |
| ▸ | UGT1A4 | P22310 | 1/20 | 0.90 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.90 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | STS | P08842 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anastrozole SCHEMBL13323725 | 0.97 | CYP19A1 (0.84) | CYP19A1UGT1A4PDE4DESR1STS | |
| Anastrozole SCHEMBL9726 | 0.95 | CYP19A1 (1.00) | CYP19A1UGT1A4PDE4DESR1STS | |
| Anastrozole SCHEMBL177942 | 0.95 | CYP19A1 (1.00) | CYP19A1UGT1A4PDE4DESR1STS | |
| Anastrozole SCHEMBL27927481 | 0.95 | CYP19A1 (1.00) | CYP19A1UGT1A4PDE4DESR1STS | |
| Anastrozole SCHEMBL28771766 | 0.93 | CYP19A1 (0.97) | CYP19A1UGT1A4PDE4DESR1STS | |
| Anastrozole SCHEMBL5917785 | 0.93 | CYP19A1 (0.97) | CYP19A1UGT1A4PDE4DESR1STS | |
| Anastrozole SCHEMBL3172308 | 0.93 | CYP19A1 (0.97) | CYP19A1UGT1A4PDE4DESR1STS | |
| SCHEMBL10324455 | 0.91 | CYP19A1 (0.92) | CYP19A1UGT1A4PDE4DESR1STS | |
| SCHEMBL8059026 | 0.88 | CYP19A1 (0.87) | CYP19A1UGT1A4PDE4DESR1STS | |
| Anastrozole SCHEMBL13323738 | 0.88 | CYP19A1 (0.70) | CYP19A1UGT1A4PDE4DESR1STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100111901-A1 | TRIAZOLE INHIBITORS OF AROMATASE | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100111901-A1 | TRIAZOLE INHIBITORS OF AROMATASE | CYP19A1, CYP17A1, HSD17B11 | CYP19A1 1/4885UGT1A4 98/4885PDE4D 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.